Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — November 2023

Genmab — November 2023

Planlagt Fastgjort Låst Flyttet Genmab
1.5k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • T Offline
    T Offline
    Teller
    wrote on sidst redigeret af
    #1421

    Hvis renten forbliver mellem 3,5 - 5 % frem til patentudløb, og på den baggrund af nuværende pipeline status, er kurs 2000 - 2400 kr vel ikke helt ved siden af.

    1 Reply Last reply
    0
    • StockBullS Offline
      StockBullS Offline
      StockBull
      wrote on sidst redigeret af
      #1422

      Renten bliver normalt sænket meget hvis der er recession. En recession er jo tegn på økonomien går ad H til. Typisk vil en recession være årsagen til, at obligationskurserne stiger – og renterne falder meget – da det får centralbanken til at sænke renten og stimulere økonomien, mens investorerne søger sikker havn i statsobligationerne.

      1 Reply Last reply
      0
      • B Offline
        B Offline
        bibob
        wrote on sidst redigeret af
        #1423

        Børsen kl 10. Genmab partner falder 17 % efter fejlet forsøg.

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #1424

          yea... another day another biotech getting slammed...

          1 Reply Last reply
          0
          • T Offline
            T Offline
            Teller
            wrote on sidst redigeret af
            #1425

            Har Genmab overhovedet del i deres fejlede bløder medicin?

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #1426

              no, not at all

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #1427

                Novartis approximates Kesimpta Peak sales at $4bn in their investor presentation https://www.novartis.com/sites/novartiscom/files/novartis-investors-r-d-day-2023.pdf

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #1428

                  Genmab A/S (NASDAQ:GMAB) Stock Rating Reaffirmed by HC Wainwright -"buy" rating restated by stock analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $49.00 target price

                  1 Reply Last reply
                  0
                  • K Offline
                    K Offline
                    Klarussen
                    wrote on sidst redigeret af
                    #1429

                    Hvis den gik 3% ned i går på en "hold" anbefaling, så burde det her da kunne løfte den med et kursmål sv.t. 3332 kr.

                    1 Reply Last reply
                    0
                    • W Offline
                      W Offline
                      w
                      wrote on sidst redigeret af
                      #1430

                      Når der først er gået sur røv i en aktie, så
                      ser det svært ud

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        lahn1
                        wrote on sidst redigeret af
                        #1431

                        Tror ikke fib 61,8 holder her. Tror vi skal have lukket det gap i 2035 imorgen. Så er vi også klar til ny op-tur frem mod ASH.

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #1432

                          3rd attempt for the German 10y bund yield to break below the 2.50% level this month; hopefully that can give us a bit of headwind...

                          1 Reply Last reply
                          0
                          • SolsenS Offline
                            SolsenS Offline
                            Solsen
                            wrote on sidst redigeret af
                            #1433

                            Tak EL (11:30) - Kesimpta fylder efterhånden en del i værdiansættelsen af Genmab.

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #1434

                              FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous

                              1 Reply Last reply
                              0
                              • K Offline
                                K Offline
                                Klarussen
                                wrote on sidst redigeret af
                                #1435

                                E L: can you enlighten us novices to the importance of this information in regard to Genmab?

                                1 Reply Last reply
                                0
                                • K Offline
                                  K Offline
                                  Klarussen
                                  wrote on sidst redigeret af
                                  #1436

                                  @w 15:50: spot on, gælder iøvrigt for mange andre fohold i livet end aktier

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #1437

                                    https://firstwordpharma.com/story/5804477?from=article For Genmab er det Carvykti der er interessant. Er af JNJ slået op til noget stort i myeloma - dara konkurrent. Så dette er meget vigtig for Genmab.

                                    1 Reply Last reply
                                    0
                                    • K Offline
                                      K Offline
                                      Klarussen
                                      wrote on sidst redigeret af
                                      #1438

                                      Tak Solsen

                                      1 Reply Last reply
                                      0
                                      • BulderB Offline
                                        BulderB Offline
                                        Bulder
                                        wrote on sidst redigeret af
                                        #1439

                                        Ikke så heldigt hvis en kræftbehandling er kræftfremkaldende.

                                        1 Reply Last reply
                                        0
                                        • T Offline
                                          T Offline
                                          Teller
                                          wrote on sidst redigeret af
                                          #1440

                                          "FDA is investigating the identified risk of T-cell malignancy with serious outcomes, including hospitalisation and death, and is evaluating the need for regulatory action"

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper